RNAZ - TransCode Therapeutics, Inc. Sotuvning sof marjinal rentabelligi

TransCode (RNAZ) - korporativ logo

TransCode Therapeutics (RNAZ) klinik sinovlar orqali qattiq o'smalarga qarshi kurashish uchun o'zining RNA platformasini kengaytirmoqda. Haqiqiy sof foyda marjasi joriy biznes dinamikasini aks ettiradi va ushbu ko'rsatkich 0.00 darajasida turibdi. Istiqbollar metastazlarni yo'q qilish uchun temir oksidi nanoparticleslariga hamda onkogenlarni faolsizlashtiruvchi aniq genetik vositalarni ishlab chiqishda brendning yuqori nufuziga tayanadi.

transcodetherapeutics.com (RNAZ) Sof foyda normasi: 04.07.2022 - 19.11.2026 davri uchun

transcodetherapeutics.com (RNAZ) kompaniyasining tahliliy kesimlari

- aksiya kursi va ekspertlarning narx prognozi:
Kompaniyaning har tomonlama tahlili:TransCode, RNAZ
TransCode Therapeutics ishlab chiqargan mahsulot

TransCode Therapeutics (RNAZ) faol savdolarsiz, o'zining DNA platformasining preklinik sinovlariga e'tibor qaratgan erta bosqichdagi biotexnologiya startapi sifatida faoliyat yuritadi. Bunday sharoitda, daromadning yo'qligi sof foyda marjasini hisoblashni matematik jihatdan beqaror qiladi. Ushbu ko'rsatkich barcha operatsion va soliq xarajatlari chegirib tashlanganidan keyin kompaniya saqlab qolgan foyda foizini o'lchaydi. Sof foyda marjasini tahlil qilish orqali investor joriy aktivlarni monetizatsiya qilish samaradorligini baholaydi. Ushbu metrikaning tendentsiyasi biznesning grantlar hisobiga yashab qolish bosqichidan tijorat realizatsiyasiga o'tishini aks ettiradi.

Raqobatchilar tahlili

TEM: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha marjinallik Qiagen QGEN|IONS (Isis Pharmaceuticals) - Sotuvning sof marjinal rentabelligi|Repligen Inc. - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi RNA|CRSP - Sof marja|GeneDx - Sof foyda bo'yicha sotuv rentabelligi|Sof foyda normasi RARE|Beam Tx - Sotuvning sof marjinal rentabelligi|SRPT - Sotuvning sof marjinal rentabelligi|TWST (Twist Bio) - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof rentabelligi TXG|Sof foyda bo'yicha sotuv rentabelligi NTLA|Stoke Therapeutics Inc (STOK) - Kompaniya sotuv marjasi|Sotuvning sof marjinal rentabelligi BLFS|Sof marja WVE (Wave Life Sciences Corp)|Sof marja Maze Therapeutics MAZE|Sof foyda normasi SION|PRME - Sof marja|Kompaniya sotuv marjasi Taysha TSHA|QURE: Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MeiraGTx PLC|RGNX (REGENXBIO Inc) - Sotuvning sof marjinal rentabelligi|solidbio.com (SLDB) - Kompaniya sotuv marjasi|Sof marja Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Sotuvning sof rentabelligi|Benitec Biopharma - Sof foyda bo'yicha sotuv rentabelligi|DSGN: Sotuvning sof rentabelligi|RCKT: Sof foyda bo'yicha sotuv rentabelligi|FDMT - Sotuvning sof marjinal rentabelligi|LXEO: Sotuvning sof marjinal rentabelligi|Korro Bio Inc. - Sof foyda normasi|EDIT (editasmedicine.com) - Sotuvning sof marjinal rentabelligi|Sof marja SLN|Sof marja ProQR Therapeutics NV (PRQR)|Codexis - Sotuvning sof rentabelligi|Sof marja Sangamo SGMO|NAUT: Sotuvning sof rentabelligi|MGX: Sof foyda bo'yicha sotuv rentabelligi|Sof marja Precision BioSciences|GBIO (generationbio.com) - Sof foyda bo'yicha sotuv rentabelligi|Sof marja boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi IMNN (Imunon, Inc.)|Sotuvning sof marjinal rentabelligi PHIO|MBIO - Sof marja|Sof marja Bionano Genomics BNGO|Sof foyda normasi APDN|BLUE - Sof marja|Sof foyda marjasi IPA|Omega Therapeutics, Inc. (OMGA) - Sof marja|Singular Genomics Corp (OMIC) - Sotuvning sof marjinal rentabelligi|RGLS (Regulus Therapeutics, Inc.) - Sotuvning sof marjinal rentabelligi|SYRS: Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi TBIO (Telesis Bio Inc.)|Sotuvning sof marjinal rentabelligi TRACON Pharmaceuticals Inc. (TCON)|Sof marja Unity Bio UBX